In 2007, Françoise Baylis and Jason Scott Robert published “Part-Human Chimeras: Worrying the Facts, Probing the Ethics” in The American Journal of Bioethics. Within their article, hereafter “Part-Human Chimeras,” the authors offer corrections on “Thinking About the Human Neuron Mouse,” a report published in The American Journal of Bioethics in 2007 by Henry Greely, Mildred K. Cho, Linda F. Hogle, and Debra M. Satz, which discussed the debate on the ethics of creating part-human chimeras. Chimeras are organisms that contain two or more genetically distinct cell lines. Both publications discuss chimeras with DNA from different species, specifically in response to studies in which scientists injected human brain cells into mice. “Part-Human Chimeras,” contributes to a chain of ethical and scientific discussion that occurred in the mid-2000s on whether people should be able to conduct research on chimeras, especially in embryos.

A lymphoblastoid cell line, or LCL, is an immortalized population of cells derived from a specific type of white blood cell called a B lymphocyte that scientists around the world began using for biomedical research in the late 1960s. By immortalized, scientists mean that the cells have been altered so they can grow and divide indefinitely, or at least for an extended period of time. That trait of LCLs makes them useful as a replenishable source of cells and the DNA contained within them. Scientists obtain LCLs by first collecting a blood sample and then exposing the B lymphocytes in the blood to Epstein-Barr virus, or EBV. EBV alters the B lymphocytes in such a way that the cells begin to multiply without restraint. Researchers began making and storing LCLs from individuals around the world in the 1960s. As of 2025, LCLs form a mainstay of biomedical research, especially in human genetics and genomics.